MELK and nonpapillary renal cell carcinoma: Studies have documented that the oncogenic effect of MELK in ccRCC is exerted through the phosphorylation of PRAS40, an inhibitory subunit of mTORC1, and by disrupting the interaction between PRAS40 and raptor (Zhang et al., 2019b).